UBS AM
CMPX icon

UBS AM’s Compass Therapeutics CMPX Stock Holding History

UBS AM’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Buy
177,814
+38,172
+27% +$113K ﹤0.01% 2600
2026
Q1 		$739K Buy
+139,642
New +$806K ﹤0.01% 2443

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM's CMPX Position: Q2 2026 in Review

UBS AM increased its Compass Therapeutics (CMPX) stake by 27% in Q2 2026, buying an estimated $113K and bringing the position to 177,814 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

UBS AM first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $739K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • UBS AM held 177,814 shares of Compass Therapeutics worth $389K as of Q2 2026.
  • UBS AM bought 38,172 Compass Therapeutics shares in Q2 2026, an estimated $113K.
  • Compass Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2600 holding.
  • UBS AM first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • UBS AM's Compass Therapeutics position peaked at $739K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.